Friday, February 21, 2020 3:25 PM
Stephen Amato, Ph.D.
Professor, Master of Science in Regulatory Affairs for Drugs, Biologics, and Medical Devices
Tuesday, February 11, 2020 3:25 PM
Or Perlman, Ph. D.
MGH/Martinos Center for Biomedical Imaging, Harvard Medical School
Friday, February 7, 2020 3:25 PM
Professor of the Practice, Biotechnology Programs
Tuesday, January 28, 2020 3:25 PM
Zongmin Zhao, Ph.D.
SEAS and Wyss Institute, Harvard University
25 Years of Commercializing Nanomedicine: From Increasing Bone Growth to Reducing Infections to Implantable Sensors
Friday, January 24, 2020 3:25 PM
Thomas J. Webster, Ph.D.
Art Zafiropoulo Chair, Chemical Engineering
Friday, January 17, 2020 3:25 PM
Nikos Soukos, DDS, Ph.D.,
Founder & CEO, Photomedics, Inc.
Friday, November 22, 2019 3:25 PM
Khalid Shah, MS, PhD
Vice Chair of Research, Brigham and Women’s Hospital
Director, Center for Stem Cell Therapeutics and Imaging, Harvard Medical School
Friday, November 15, 2019 3:00 PM
Peng Yin, Ph.D.
Professor of Systems Biology, Harvard Medical School
Wyss Institute, Harvard University
Drug delivery barriers in human cancer and the development of nanoparticle drug delivery systems to enhance drug delivery and therapeutic response
Friday, November 8, 2019 3:25 PM
Lily Yang, MD, PhD
Professor, Department of Surgery and Winship Cancer Institute
Emory University School of Medicine, Atlanta, GA
Friday, November 1, 2019 3:25 PM
Nikki Tennermann, LICSW
Office of Health Equity and Inclusion, Boston Children’s Hospital
Friday, October 25, 2019 3:25 PM
Manuel Sanchez-Felix, PhD
Senior Fellow, Novel Delivery Technologies Group
Novartis Institutes for BioMedical Research
Tuesday, October 22, 2019 3:25 PM
Sayeda Yasmin-Karim, MD
Department of Radiation Oncology,
Brigham and Women’s Hospital /Harvard Medical School
Friday, October 18, 2019 3:25 PM
Stephanie Dougan, Ph.D.
Assistant Professor, Microbiology and Immunobiology, Harvard Medical School
Tuesday, October 8, 2019 3:25 PM
Needa Virani, Ph.D.
Scientist in Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital
Tuesday, September 24, 2019 3:25 PM
Rong Liu, M.D., Ph.D.,
Department of Surgery, MGH
Instructor in Surgery, Harvard Medical School
Jelena M. Janjic1,2,3
September 25, 2:50 pm, Snell Library 125
1Graduate School of Pharmaceutical Sciences, Duquesne University School of Pharmacy, Pittsburgh, PA, USA E-mail: firstname.lastname@example.org
2Chronic Pain Research Consortium, Duquesne University, Pittsburgh, PA, USA
3McGowan Institute of Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Theranostic nanoparticles are emerging technology for imaging and drug delivery. The focus of this talk is on theranostic fluorous nanocolloids based on triphasic nanoemulsion formulations (Scheme 1), first reported by our laboratory in 2012, and since expanded into threranostic nanoformulation platform applicable for cancer, inflammation and pain imaging and treatment. Earlier reported perfluorocarbon nanoemulsions were two-phase systems with PFC oil as an internal phase and where the surfactant layer incorporated a drug, dye and/or a targeting agent. (Aikers et al, Nanomedicine 2010, Soman et al, Nano Lett. 2008) Our approach was to introduce a “third” phase – organic (hydrocarbon oil) into the PFC nanoemulsion while maintaining small droplet size (85-140 nm) and polydispersity (PDI<0.15). (O’Hanlon et al, JFluoChem 2012, Mountain et al, JFluo Chem 2014, Patel et al, PLOS One 2013, Janjic et al, Biomaterials 2014) These nanoemulsions are triphasic because they are constituted from three immiscible liquids: PFC (fluorous phase), hydrocarbon (organic phase) and water (aqueous phase). Representative results from in vitro and in vivo studies in multiple animal models will be presented to demonstrate the broad utility of triphasic nanoemulsions as theranostic nanomedicines for inflammatory diseases, injury, and pain. Further, I will discuss unique challenges nanomedicine meets which can hinder future clinical translation and commercialization. Our lab takes earlier established approaches in the wider pharmaceutical industry such as quality by design (QbD) and adapts them to the development and production fluorous colloids nanomedicine. Following these methods, we are able to develop robust processes for scale-up, quality control, and clinical translation. Recent results from these studies will also be presented.